Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data

Pedersini, Rebecca; Mauro, Pierluigi di; Amoroso, Vito; Parati, Maria Chiara; Turla, Antonella; Ghilardi, Mara; Vassalli, Lucia; Ardine, Mara; Volta, Alberto Dalla; Monteverdi, Sara; Borgonovo, Karen; Ghidini, Antonio; Cabiddu, Mary; Simoncini, Edda; Petrelli, Fausto; Berruti, Alfredo; Barni, Sandro

doi:10.1016/j.jgo.2020.03.021

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В 2020 г. был представлен объединенный анализ 5 исследований с включением 301 больной старшей возрастной группы (≥70 лет), получившей лечение эрибулином по поводу мРМЖ [31]. Объективный ответ на терапию эрибулином достигнут у 23,2 % больных, контроль болезни -у 47 %; медиана ВБП и ОВ составила 4,8 и 13,1 мес соответственно.…”

Section: обзорные статьиunclassified

“…Редукция дозы эрибулина потребовалась в 40 % случаев. Авторы резюмируют, что профиль эффективности и безопасности химиотерапии эрибулином у пациентов пожилого возраста соответствует общепопуляционному; препарат демонстрирует хороший баланс между эффективностью и безопасностью при предлеченном мРМЖ [31].…”

Section: обзорные статьиunclassified

See 1 more Smart Citation

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

Колядина

2021

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the antitumor activity displayed by the drug. Among those presented, there are significant retrospective studies evaluating the role of eribulin chemotherapy in late and early advanced breast cancer treatment lines, as well as an analysis of surveys aimed to evaluate the efficacy of the drug in various clinical settings (for visceral metastases, brain lesion, and in elderly patients). This article reflects the main results of Russian population analyses evaluating the efficacy and safety of eribulin chemotherapy in routine clinical practice.

show abstract

Section: обзорные статьиunclassified

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

Колядина

2021

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

show abstract

“…In addition, eribulin inhibits tumor progression or metastasis by reducing hypoxia [ 25 ], reversing epithelial–mesenchymal transition [ 26 ], suppressing migration and invasion [ 26 ], and preventing tumor vasculature remodeling [ 25 ]. Eribulin has been used to treat advanced or metastatic breast cancer, including TNBC [ 27 , 28 , 29 ], and has been used to overcome chemotherapy resistance. Eribulin produced regression of cisplatin-resistant tumors in a patient-derived xenograft model of triple-negative matrix-producing breast carcinoma [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

et al. 2023

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the survival of TNBC patients. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is approved by the U.S. Food and Drug Administration to treat metastatic breast cancer after at least two previous chemotherapeutic regimens. However, eribulin as a single agent has limited therapeutic efficacy against TNBC. Methods: High-throughput kinome library RNAi screening, Ingenuity Pathway Analysis, and STRING analysis were performed to identify target kinases for combination with eribulin. The identified combinations were validated using in vivo and ex vivo proliferation assays. Results: We identified 135 potential kinase targets whose inhibition enhanced the antiproliferation effect of eribulin in TNBC cells, with the PI3K/Akt/mTOR and the MAPK/JNK pathways emerging as the top candidates. Indeed, copanlisib (pan-class I PI3K inhibitor), everolimus (mTOR inhibitor), trametinib (MEK inhibitor), and JNK-IN-8 (pan-JNK inhibitor) produced strong synergistic antiproliferative effects when combined with eribulin, and the PI3K and mTOR inhibitors had the most potent effects in vitro. Conclusions: Our data suggest a new strategy of combining eribulin with PI3K or mTOR inhibitors to treat TNBC.

show abstract

“…Decisionmaking for cancer treatment adherence, type, and decisions to have surgical intervention negatively affect both patient and family caregivers (Advani et al, 2022;Alatawi et al, 2021;Al-Rashdan et al, 2021). Also, the risk of hospitalization due to chemotherapy use (Valachis et al, 2021) and low but possible risk of chemotherapy toxicity (Pedersini et al, 2020) add to the stress experienced by female breast cancer patients and their caregivers. While surgical intervention may be an option in breast cancer treatment (Jauhari et al, 2021), the decision by older women with breast cancer or their family caregivers to elect for surgical intervention may be deterred by the choice to use adjuvant therapies (Karuturi et al, 2022) along with the age of the patient (Liu et al, 2021;Morgan et al, 2021)-potentially resulting in the caregiving stress experienced by family caregivers (Jansen et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

A Scoping Review of the Physical Health Needs of Family Caregivers of Older Women With Breast Cancer

Felix¹,

Kitcharoen²,

Le³

et al. 2022

JPSS

View full text Add to dashboard Cite

This scoping review conducted mapping of relevant literature on the physical health needs of family caregivers of older women with breast cancer, gaps analysis, and suggests directions for future academic research. The PRISMA-ScR checklist by Tricco et al. (2018) guided the scoping review. Ten international databases were searched for academic articles published in English between January 2002 and January 2022. The 12,795 discovered articles were reduced to two sources of evidence. Extracted data were mapped out using a charting table. The analysis revealed a dearth of research on the subject of physical health of family caregivers of older women with breast cancer, a lack of detailed description of the physical health needs of family caregivers of older women with breast cancer, a lack of cultural, geographic, and ethnic diversity, a lack of studies on the physical needs/strains experienced by family caregivers aside from physical activity needs, underutilized research methodologies, gender differences that influence physical health needs of family caregivers, development of research tools, and lack of intervention/educational programs on physical health for family caregivers. Future research directions were suggested, and limitations were presented.

show abstract

Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data

Cited by 6 publications

References 49 publications

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines

A Scoping Review of the Physical Health Needs of Family Caregivers of Older Women With Breast Cancer

Contact Info

Product

Resources

About